Prothena to Report Second Quarter 2022 Financial Results on August 8th
Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first six months of 2022 financial results on August 8, 2022, after U.S. market close. The company will not hold a conference call to discuss these results, adhering to past practices. Prothena specializes in developing therapeutics targeting neurodegenerative diseases and amyloid disorders, leveraging extensive research expertise. Their pipeline includes treatments for conditions such as AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, and Parkinson's disease.
- Prothena has a robust pipeline targeting serious neurological diseases, indicating potential for future growth.
- The company specializes in protein dysregulation, a critical area in developing new therapeutics.
- Absence of a conference call may limit investor engagement and clarity on financial results.
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Contacts:
Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, eric.endicott@prothena.com
FAQ
When will Prothena report its financial results for Q2 2022?
Is there a conference call scheduled for Prothena's financial results?
What diseases is Prothena targeting with its therapeutics pipeline?
What is Prothena's stock symbol?
